Respiratory Syncytial Virus

CalendarToday
timer
1 min read
Respiratory Syncytial Virus Blog Image

Overview:

Recently, European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV).

Why in news?

  • The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.

Key facts about Respiratory Syncytial Virus:

  • It is a common respiratory virus that usually causes mild, cold-like symptoms.
  • It is serious infects infants and older adults.
  • It is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children younger than 1 year of age in the United States.
  • The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot.

What is virus?

  • A virus is an infectious microbe consisting of a segment of nucleic acid (either DNA or RNA) surrounded by a protein coat.
  • It cannot replicate alone; instead, it must infect cells and use components of the host cell to make copies of itself.

 


Q1) What is Ribonucleic Acid?

Ribonucleic Acid, is a molecule that plays a fundamental role in various biological processes. It is composed of a chain of nucleotides and is structurally similar to DNA (Deoxyribonucleic Acid). However, RNA differs from DNA in several ways, including its single-stranded structure, the presence of the sugar ribose instead of deoxyribose, and the base uracil (U) instead of thymine (T).

Source: EU approves its first vaccine for common respiratory virus RSV